Bennet, Cornyn Introduce Legislation to Lower Prescription Drug Costs and Increase Access to Biosimilars 

Washington, D.C. — Colorado U.S. Senator Michael Bennet and Senator John Cornyn (R-Texas) introduced the Increasing Access to Biosimilars Act, legislation that would direct the Department of Health and Human Services (HHS) to Create a Medicare pilot program to expand access to lower-cost alternatives to expensive biologic medicines that are as safe and effective as […]

Nov 20, 2026 | Press Releases

Washington, D.C. — Colorado U.S. Senator Michael Bennet and Senator John Cornyn (R-Texas) introduced the Increasing Access to Biosimilars Act, legislation that would direct the Department of Health and Human Services (HHS) to Create a Medicare pilot program to expand access to lower-cost alternatives to expensive biologic medicines that are as safe and effective as the original drugs. These medicines treat a range of serious conditions, including rheumatoid arthritis, Crohn’s disease, and certain types of cancer, such as breast cancer.

“Skyrocketing prescription drug prices are causing too many Americans to have to choose between their life-saving medications and putting food on the table, especially seniors, communities of color, and the millions of people living on fixed incomes who need their prescriptions to live,” said Bennet. “This important legislation would increase patient access to lower-cost biosimilars, saving them and our health care system billions of dollars. Every American deserves affordable health care, and I look forward to working with my colleagues to move this legislation forward.” 

“Texas seniors should not have to break the bank to pay for their medication that’s essential to their health and well-being, yet millions are being forced to endure this financial burden because of the skyrocketing cost of prescription drugs,” said Cornyn. “I am proud to co-lead this bipartisan legislation to help ensure our seniors can afford the treatments they need by expanding access to biosimilars, which lowers drug costs for patients and alleviates the burden on Medicare beneficiaries.”

Currently, providers in Medicare Part B are reimbursed for administering biologic drugs, including biosimilars, at average sales price plus +6 percent, of which the federal government pays 80 percent, and beneficiaries pay 20 percent coinsurance. This means providers are reimbursed at a higher rate for using higher-cost biologic products rather than lower-cost biosimilars. At the same time, Medicare beneficiaries are forced to pay higher copays on those brand name biologic products. 

This legislation would direct HHS to establish a shared savings demonstration project to increase access to biosimilars in the Medicare Part B program. Under the demonstration, Medicare would provide an additional payment to providers for using lower-cost biosimilar products, reflecting savings created in contrast to administering higher-cost reference biologic drugs. Additionally, Medicare can use a portion of those savings to reduce the beneficiary’s coinsurance payment. This would encourage physicians to prescribe less-expensive biosimilars, increasing patient access to more affordable, life-saving drugs and lowering patient out-of-pocket costs.

Under the demonstration, Medicare would provide an additional payment to providers for using lower-cost biosimilar products that reflects the savings created in contrast to administering the higher-cost reference biological product. Additionally, Medicare can use a portion of those savings to reduce the beneficiary’s coinsurance payment.

The Increasing Access to Biosimilar Act is supported by the Biosimilars Forum, Association for Accessible Medicines, Viatris, Biosimilars Council, and American Podiatric Medical Association.

“Biosimilars are the commonsense, proven solution to America’s prescription drug affordability crisis. The Biosimilars Forum thanks Senators Bennet and Cornyn for their bipartisan leadership, and we urge Congress to pass this important bill,” said Juliana M. Reed, executive director of the Biosimilars Forum. “Biosimilars have already saved the U.S. health care system $81.6 billion, including $25.4 billion in 2025 alone. The Increasing Access to Biosimilars Act builds on that record by realigning Medicare Part B incentives so more seniors can access these lower-cost medicines. We are entering the second decade of biosimilars. The first decade proved the science. The second decade is about delivering the full promise of biosimilars. This means new products coming to market and new savings for patients, taxpayers, and the health care system.”

“The Biosimilars Council and the Association for Accessible Medicines thank Senators Bennett and Cornyn for their work and dedication on behalf of American patients with the reintroduction of the Increasing Access to Biosimilars Act,” said Alex Keeton, Executive Director, Biosimilars Council. “This bipartisan bill is based on a simple idea – that Medicare policies should encourage and prioritize the most effective, lowest-cost medicine. Biosimilars consistently deliver significant savings compared to high-priced brand biologics. We encourage Congress and the Administration to quickly implement this policy and deliver savings to America’s patients and taxpayers, and to put generic and biosimilar medicines first.” 

Bennet has consistently worked to bring down prescription drug costs for Coloradans. In October, Bennet hosted Colorado parents, seniors, and caregivers as well as pharmacists, senior advocates, and health care leaders for a discussion on high-cost prescriptions and access to affordable medications. In April 2026, Bennet joined Senator Ron Wyden (D-Ore.) and 16 Senate Democrats to introduce legislation to force the Trump Administration to disclose the terms of deals the administration made with more than a dozen of the largest pharmaceutical companies, and conduct an independent analysis to determine whether American families will actually see lower prices from the deals. Additionally, in February 2026, Bennet’s Prescription Drug Supply Chain Pricing Transparency Act was passed into law. This legislation will require the Government Accountability Office to conduct a study and submit a report to Congress about the ways the current pharmaceutical drug supply chain structure encourages drug manufacturers, Pharmacy Benefit Managers, insurance companies, and other actors to hike up drug prices. 

In December 2025, Bennet demanded four major pharmaceutical companies provide specific details about agreements they announced with President Donald Trump to lower drug costs as millions of Americans saw the cost of health care skyrocket. In March 2023, he urged the Center for Medicare and Medicaid Services Administrator Chiquita Brooks-LaSure to ensure swift implementation of the Inflation Reduction Act (IRA) provisions that will lower the cost of Medicare Part B prescription drugs. In August 2022, Bennet helped secure enhanced health insurance premium tax credits and the requirement for Medicare to negotiate drug prices in the IRA, first introduced as part of his Medicare-X public option bill.

The text of the bill is available HERE. 

###